Here we describe SGN-CD19B, a new CD19-targeted antibody-drug conjugate (ADC), which demonstrates potent preclinical activity against B-cell malignancies. SGN-CD19B is composed of a humanized antibody (hBU12ec) conjugated to a DNA-cross linking pyrrolobenzodiazepine (PBD) dimer drug (SGD-1882...
Abstract 625: Preclinical characterization of an auristatin-based anti-CD19 drug conjugate, SGN-19A CD19 has multiple attributes that make it an attractive target for an antibody-drug conjugate (ADC). CD19 is uniformly expressed on the cell surface of almost all malignancies of B cell origin, ...